Lovenox ANDA Approval In 2008 Is “Not Out Of Reach,” Momenta CEO Wheeler Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Chief exec optimistic that FDA will not require any additional clinical trials to move filing forward.